Clinical Trial Update: Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety, tolerability, and effectiveness of rasagiline mesylate in patients with Parkinson's disease; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Rasagiline mesylate (RASAGILINE MESYLATE)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED